Mechanistically, ERCC6L could accelerate the cell cycle by regulating the p53/p21/CDK1/Cyclin B and PLK/CDC25C/CDK1/Cyclin B signalling pathways, thereby promoting the malignant progression of breast cancer cell lines. This evidence concerns the gene TP53 and breast carcinoma.